![]() ![]() Takeda Pharmaceutical Company Limited Teva Pharmaceutical Industries Ltd. Novartis AG Otsuka Pharmaceutical Co., Ltd. Janssen Global Services, LLC Merck & Co., Inc. Lundbeck A/S Johnson & Johnson Services, Inc. BIAL Group Bristol-Myers Squibb Company Eisai Co., Ltd. Latin America will expand at a 8.6% CAGR through the analysis period.ĪbbVie Inc. ![]() China will remain among the fastest growing in this cluster of regional markets. These regional markets accounting for a combined market size of US$7.4 Billion in the year 2020 will reach a projected size of US$11.2 Billion by the close of the analysis period. In the global Neurovascular Diseases segment, USA, Canada, Japan, China and Europe will drive the 6.6% CAGR estimated for this segment. Neurovascular Diseases Segment to Record 6.6% CAGR Once the dialogue box opens, you can either update your monitor driver or install the INF file you downloaded earlier. ![]() Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$15.1 Billion by the year 2027. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.8% and 5.6% respectively over the 2020-2027 period. China, the world`s second largest economy, is forecast to reach a projected market size of US$14.7 Billion by the year 2027 trailing a CAGR of 9.7% over the analysis period 2020 to 2027. is estimated at US$42.8 Billion in the year 2020. Market is Estimated at $42.8 Billion, While China is Forecast to Grow at 9.7% CAGR Taking into account the ongoing post pandemic recovery, growth in the Mental Health segment is readjusted to a revised 6.1% CAGR for the next 7-year period. Neurodegenerative Diseases, one of the segments analyzed in the report, is projected to record a 6.9% CAGR and reach US$60.6 Billion by the end of the analysis period. In the changed post COVID-19 business landscape, the global market for CNS Therapeutics estimated at US$105.3 Billion in the year 2020, is projected to reach a revised size of US$161.4 Billion by 2027, growing at a CAGR of 6.3% over the analysis period 2020-2027. Global CNS Therapeutics Market to Reach $161.4 Billion by 2027 Online interactive peer-to-peer collaborative bespoke updatesĪccess to our digital archives and MarketGlass Research Platform 10, 2022 (GLOBE NEWSWIRE) - announces the release of the report "Global CNS Therapeutics Industry". Lundbeck will share 50 per cent of net sales in Europe and Canada, and 45 per cent of net sales in the US.New York, Oct. Others suggest its profile would have to be very much improved indeed to offset the much lower cost of generic aripiprazole. Lundbeck and Otsuka renewed their CNS alliance on the back of US approval of Abilify Maintena last March, extending it to include a candidate for Alzheimer's disease called Lu AE58054 a couple of weeks later.Īnalysts have suggested Abilify Maintena could achieves sales of $800m-plus in 2018 with some suggesting brexpiprazole could reach more than $2bn at peak, provided its profile shows an advantage over aripiprazole. ![]() Lundbeck noted that three additional studies of brexpiprazole in depression and schizophrenia are due to report results in the first half of 2014 and - if positive - could support a brexpiprazole filing in the US before the end of the year.Īpproval would reinforce Lundbeck and Otsuka's central nervous system franchise, which was also boosted last year by the approval of a once-monthly formulation of aripiprazole - Abilify Maintena - which is expected to be a big growth driver for both companies in the coming years. Like its parent, brexpiprazole is also positioned initially as an add-on therapy in depression but with an improved tolerability profile, and Otsuka and Lundbeck have said they saw a number of benefits over antidepressant therapy alone in the phase III study.Īdding brexpiprazole to existing antidepressant therapy achieved a significant improvement in the Montgomery-Åsberg Depression Rating Scale (MADRS) compared to placebo - the primary endpoint in the trial - as well as a series of secondary efficacy endpoints. While aripiprazole's primary use is in schizophrenia and bipolar disorder, it has increasingly been used as an add-on treatment for adults with major depressive disorder (MDD) who continue to have unresolved symptoms after at least six weeks on antidepressant therapy. The first phase III data on Otsuka and Lundbeck's new antidepressant brexpiprazole is positive and will be presented at a conference in March, said the companies last week.īrexpiprazole (OPC-34712) is a dopamine D2 and serotonin 5-HT1A partial agonist in development as a successor to the two companies' atypical antipsychotic Abilify (aripiprazole) - the top-selling drug in the US in the third quarter of 2013.Ībilify has already lost patent protection in a number of markets, however, and loses exclusivity in the US in April 2015 when the market will open up to generic competition. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |